HK1078482A1 - Modified nucleosides for treatment of viral infections and abnormal cellular proliferation - Google Patents
Modified nucleosides for treatment of viral infections and abnormal cellular proliferationInfo
- Publication number
- HK1078482A1 HK1078482A1 HK05110563.1A HK05110563A HK1078482A1 HK 1078482 A1 HK1078482 A1 HK 1078482A1 HK 05110563 A HK05110563 A HK 05110563A HK 1078482 A1 HK1078482 A1 HK 1078482A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- treatment
- viral infections
- cellular proliferation
- modified nucleosides
- abnormal cellular
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title 1
- 230000002159 abnormal effect Effects 0.000 title 1
- 230000004663 cell proliferation Effects 0.000 title 1
- 125000003835 nucleoside group Chemical group 0.000 title 1
- 230000009385 viral infection Effects 0.000 title 1
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 abstract 1
- 241000710781 Flaviviridae Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- PPBOKXIGFIBOGK-BDTUAEFFSA-N bvdv Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)C(C)C)[C@@H](C)CC)C1=CN=CN1 PPBOKXIGFIBOGK-BDTUAEFFSA-N 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24148800P | 2000-10-18 | 2000-10-18 | |
US28215601P | 2001-04-06 | 2001-04-06 | |
PCT/US2001/046113 WO2002032920A2 (en) | 2000-10-18 | 2001-10-18 | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1078482A1 true HK1078482A1 (en) | 2006-03-17 |
Family
ID=26934330
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05110563.1A HK1078482A1 (en) | 2000-10-18 | 2005-11-22 | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
HK11102651.3A HK1148470A1 (en) | 2000-10-18 | 2011-03-16 | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11102651.3A HK1148470A1 (en) | 2000-10-18 | 2011-03-16 | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
Country Status (16)
Country | Link |
---|---|
US (3) | US20030087873A1 (xx) |
EP (2) | EP2251015B1 (xx) |
JP (4) | JP2004533406A (xx) |
KR (6) | KR101005299B1 (xx) |
CN (2) | CN1646141B (xx) |
AT (1) | ATE491459T1 (xx) |
AU (4) | AU2874902A (xx) |
BR (1) | BR0114837A (xx) |
CA (1) | CA2426187C (xx) |
CY (1) | CY1111332T1 (xx) |
DE (1) | DE60143672D1 (xx) |
DK (2) | DK1411954T3 (xx) |
ES (1) | ES2402597T3 (xx) |
HK (2) | HK1078482A1 (xx) |
PT (2) | PT2251015E (xx) |
WO (1) | WO2002032920A2 (xx) |
Families Citing this family (262)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE414520T1 (de) * | 2000-04-13 | 2008-12-15 | Pharmasset Inc | 3 oder 2 hydroxymethyl substituierte nucleoside derivate und ihre verwendung zur behandlung von virusinfektionen |
MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
CA2410579C (en) | 2000-05-26 | 2010-04-20 | Jean-Pierre Sommadossi | Methods and compositions for treating flaviviruses and pestiviruses |
KR101005299B1 (ko) | 2000-10-18 | 2011-01-04 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 |
HUP0400726A3 (en) | 2001-01-22 | 2007-05-29 | Merck & Co Inc | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
US8481712B2 (en) | 2001-01-22 | 2013-07-09 | Merck Sharp & Dohme Corp. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
GB0112617D0 (en) * | 2001-05-23 | 2001-07-18 | Hoffmann La Roche | Antiviral nucleoside derivatives |
BR0214944A (pt) | 2001-12-14 | 2005-06-07 | Pharmasset Ltd | Nucleosìdeos de n4-acilcitosina para o tratamento de infecções virais |
WO2003062256A1 (en) * | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
CA2474563C (en) * | 2002-02-13 | 2010-11-09 | Merck & Co., Inc. | Methods of inhibiting orthopoxvirus replication with nucleoside compounds |
US7022680B2 (en) * | 2002-05-30 | 2006-04-04 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases |
US7608600B2 (en) * | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
NZ537662A (en) * | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
ES2469569T3 (es) | 2002-06-28 | 2014-06-18 | Idenix Pharmaceuticals, Inc. | Prof�rmacos de nucle�sidos modificados en 2' y 3' para el tratamiento de infecciones de Flaviviridae |
RS113904A (xx) * | 2002-06-28 | 2007-02-05 | Idenix (Cayman) Limited | Ribofuranozil-citidinski estar 2'-c- metil-3'-0-l-valina za lečenje flaviridae infekcije |
AU2003256619A1 (en) | 2002-07-24 | 2004-02-09 | Isis Pharmaceuticals, Inc. | Pyrrolopyrimidine thionucleoside analogs as antivirals |
JP4709545B2 (ja) | 2002-07-26 | 2011-06-22 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 修飾された低分子干渉rna分子および使用方法 |
US8093380B2 (en) | 2002-08-01 | 2012-01-10 | Pharmasset, Inc. | Compounds with the bicyclo[4.2.1]nonane system for the treatment of Flaviviridae infections |
US20040067877A1 (en) | 2002-08-01 | 2004-04-08 | Schinazi Raymond F. | 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections |
CN1849142A (zh) * | 2002-11-15 | 2006-10-18 | 埃迪尼克斯(开曼)有限公司 | 2′-支链核苷和黄病毒突变 |
US7034167B2 (en) | 2002-12-06 | 2006-04-25 | Merck & Co., Inc. | Process to ribofuranose sugar derivatives as intermediates to branched-chain nucleosides |
JP5116972B2 (ja) * | 2002-12-12 | 2013-01-09 | イデニクス(ケイマン)リミテツド | 2’−分枝ヌクレオシドの製造方法 |
JP2006514038A (ja) * | 2002-12-23 | 2006-04-27 | イデニクス(ケイマン)リミテツド | 3’−ヌクレオシドプロドラッグの生産方法 |
AU2003300544A1 (en) * | 2003-01-09 | 2004-08-10 | F. Hoffmann-La Roche Ag | -modified nucleoside derivatives for treating flaviviridae infections |
AR043006A1 (es) | 2003-02-12 | 2005-07-13 | Merck & Co Inc | Proceso para preparar ribonucleosidos ramificados |
WO2004084796A2 (en) * | 2003-03-28 | 2004-10-07 | Pharmasset Ltd. | Compounds for the treatment of flaviviridae infections |
RU2358979C2 (ru) | 2003-05-30 | 2009-06-20 | Фармассет, Инк. | Модифицированные фторированные аналоги нуклеозида |
WO2005009418A2 (en) * | 2003-07-25 | 2005-02-03 | Idenix (Cayman) Limited | Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c |
WO2005018330A1 (en) * | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
US7582428B2 (en) * | 2003-08-22 | 2009-09-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for identifying anti-HCV agents |
JP2005132767A (ja) * | 2003-10-30 | 2005-05-26 | Sumitomo Chemical Co Ltd | プリン化合物の製造方法 |
US7160537B2 (en) | 2003-12-15 | 2007-01-09 | Siemens Medical Solutions Usa, Inc. | Method for preparing radiolabeled thymidine having low chromophoric byproducts |
US20050131224A1 (en) * | 2003-12-15 | 2005-06-16 | Cti Pet Systems, Inc. | Method for preparing radiolabeled thymidine |
GB0500020D0 (en) | 2005-01-04 | 2005-02-09 | Novartis Ag | Organic compounds |
US20050182252A1 (en) | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
MXPA06011141A (es) * | 2004-04-01 | 2007-08-14 | Rexahn Corp | Derivados de nucleosidos y usos terapeuticos de los mismos. |
CA2568379A1 (en) | 2004-06-15 | 2005-12-29 | Merck & Co., Inc. | C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase |
JP2008503562A (ja) * | 2004-06-23 | 2008-02-07 | イデニクス(ケイマン)リミテツド | フラビウイルス科による感染症を治療するための5−アザ−7−デアザプリン誘導体 |
EP1773355B1 (en) | 2004-06-24 | 2014-06-25 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
US20090208456A1 (en) * | 2004-07-27 | 2009-08-20 | Gilead Sciences, Inc. | Imidazo[4,5-d]pyrimidines, their uses and methods of preparation |
KR101177590B1 (ko) | 2004-09-14 | 2012-08-27 | 파마셋 인코포레이티드 | 2'-플루오로-2'-알킬 치환되거나 또는 다른 선택적으로치환된 리보퓨라노실 피리미딘 및 퓨린 및 그 유도체의제조 |
DE102004051804A1 (de) * | 2004-10-21 | 2006-04-27 | Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) | Beta-L-N4-Hydroxycytosin-Desoxynucleoside und ihre Verwendung als pharmazeutische Mittel zur Prophylaxe oder Therapie von viralen Erkrankungen |
JP5187560B2 (ja) * | 2005-01-25 | 2013-04-24 | 味の素株式会社 | ヌクレオシド誘導体の製造方法 |
CA2600359A1 (en) * | 2005-03-09 | 2006-09-09 | Idenix (Cayman) Limited | Nucleosides with non-natural bases as anti-viral agents |
WO2006130217A2 (en) * | 2005-04-01 | 2006-12-07 | The Regents Of The University Of California | Substituted phosphate esters of nucleoside phosphonates |
WO2006119061A2 (en) | 2005-05-02 | 2006-11-09 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
TWI387603B (zh) | 2005-07-20 | 2013-03-01 | Merck Sharp & Dohme | Hcv ns3蛋白酶抑制劑 |
US8278322B2 (en) | 2005-08-01 | 2012-10-02 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8067391B2 (en) | 2005-10-03 | 2011-11-29 | University Health Network | ODCase inhibitors for the treatment of malaria |
US20090270431A1 (en) * | 2005-10-19 | 2009-10-29 | The University Of Georgia Research Foundation | Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections |
GB0523041D0 (en) * | 2005-11-11 | 2005-12-21 | Cyclacel Ltd | Combination |
JP5254033B2 (ja) * | 2005-12-23 | 2013-08-07 | イデニク プハルマセウティカルス,インコーポレイテッド | 分岐型ヌクレオシドを調製するための合成中間体の製造方法 |
HUP0600042A3 (en) * | 2006-01-19 | 2012-12-28 | Debreceni Egyetem | New medical use of thiolated pyrimidine-mononucleotides and -nucleosides |
WO2007092213A2 (en) * | 2006-02-02 | 2007-08-16 | Millennium Pharmaceuticals, Inc. | Inhibitors of e1 activating enzyme |
BRPI0710878A2 (pt) | 2006-04-11 | 2015-03-31 | Novartis Ag | Compostos orgânicos e seus usos |
FR2907786B1 (fr) * | 2006-10-27 | 2009-09-18 | Univ Grenoble 1 | Thionucleosides et applications pharmaceutiques |
GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
DE102006037786A1 (de) * | 2006-08-11 | 2008-03-20 | Resprotect Gmbh | Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung |
US7655419B2 (en) * | 2006-08-25 | 2010-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for identifying anti-HCV agents |
AU2007309546A1 (en) | 2006-10-24 | 2008-05-02 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | HCV NS3 protease inhibitors |
US8309540B2 (en) | 2006-10-24 | 2012-11-13 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
CA2667146C (en) | 2006-10-24 | 2016-01-19 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
CA2667031C (en) | 2006-10-27 | 2013-01-22 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
CN101568346B (zh) | 2006-10-27 | 2015-11-25 | 默沙东公司 | Hcv ns3蛋白酶抑制剂 |
GB0625283D0 (en) | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
JP2010513450A (ja) | 2006-12-20 | 2010-04-30 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | 抗ウイルス性インドール |
GB0625345D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
GB0625349D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
JP2010515680A (ja) | 2007-01-05 | 2010-05-13 | メルク・シャープ・エンド・ドーム・コーポレイション | Rna依存性rnaウイルス感染症の治療用としてのヌクレオシドアリールホスホロアミデート |
JP2010519179A (ja) | 2007-01-17 | 2010-06-03 | アンスティトゥ・ドゥ・ルシェルシュ・クリニーク・ドゥ・モントリオール | ヌクレオシドおよび四級炭素中心を有するヌクレオチド類似体ならびに使用方法 |
EP2132215B1 (en) | 2007-02-28 | 2015-09-23 | The Governors of the University of Alberta | Compounds for preventing or treating viral infections and methods of use thereof |
BRPI0808089A2 (pt) | 2007-02-28 | 2014-07-15 | Conatus Pharmaceuticals Inc | Método para tratar uma doença do fígado, para diminuir um nível elevado de uma enzima do fígado, para inibir uma cascata de sinalização de tnf-alfa e uma cascata de sinalização de alfa-faz, para reduzir um dano ao fígado, para suprimir a apoptose excessiva em uma célula de fígado, e para inibir a replicação do vírus da hepatite c. |
EA017183B1 (ru) * | 2007-03-23 | 2012-10-30 | Саузерн Рисерч Инститьют | Способ лечения и предупреждения артрита |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
US8242120B2 (en) * | 2007-04-10 | 2012-08-14 | University Of Georgia Research Foundation, Inc. | Carbocyclic compounds and methods for treating emerging disease, including influenza and Venezuela equine encephalitis virus |
US8871435B2 (en) * | 2007-06-27 | 2014-10-28 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for identifying agents that inhibit an NS4B-mediated neoplastic cellular phenotype of HCV infected cells |
WO2009010785A1 (en) | 2007-07-17 | 2009-01-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Macrocyclic indole derivatives for the treatment of hepatitis c infections |
US8927569B2 (en) | 2007-07-19 | 2015-01-06 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as antiviral agents |
JP2011504462A (ja) | 2007-11-02 | 2011-02-10 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | 腫瘍の予防および治療のための方法および化合物 |
US20090318380A1 (en) * | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
EP2265626B1 (en) * | 2008-03-18 | 2019-05-15 | LCB Pharma Inc | Nucleotide analogues with quaternary carbon stereogenic centers and methods of use |
TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
EP2271351A4 (en) | 2008-04-03 | 2016-08-31 | Spring Bank Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS |
EA020659B1 (ru) | 2008-04-23 | 2014-12-30 | Джилид Сайэнс, Инк. | 1'-замещённые карбануклеозидные аналоги для противовирусной терапии |
WO2009134624A1 (en) | 2008-04-28 | 2009-11-05 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
JP6006938B2 (ja) | 2008-06-09 | 2016-10-12 | サイクラセル リミテッド | スパシタビン(cndac)と、デシタビン及びプロカイン等のdnaメチルトランスフェラーゼ阻害剤との組合せ |
ES2458358T3 (es) | 2008-07-02 | 2014-05-05 | Idenix Pharmaceuticals, Inc. | Compuestos y composiciones farmacéuticas para el tratamiento de infecciones víricas |
WO2010002877A2 (en) | 2008-07-03 | 2010-01-07 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
PL2540350T3 (pl) | 2008-07-22 | 2014-10-31 | Merck Sharp & Dohme | Kombinacje makrocyklicznego związku chinoksaliny, który jest inhibitorem proteazy NS3 HCV z innymi środkami przeciw HCV |
US8815829B2 (en) | 2008-12-09 | 2014-08-26 | Rfs Pharma, Llc | 3′-azido purine nucleotide prodrugs for treatment of viral infections |
KR20110104074A (ko) | 2008-12-23 | 2011-09-21 | 파마셋 인코포레이티드 | 퓨린 뉴클레오시드의 합성 |
PA8855601A1 (es) | 2008-12-23 | 2010-07-27 | Forformidatos de nucleósidos | |
US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
WO2010082050A1 (en) | 2009-01-16 | 2010-07-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections |
GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
WO2010090723A2 (en) * | 2009-02-04 | 2010-08-12 | University Of Georgia Research Foundation, Inc. | Methods of inhibiting fibrogenesis and treating fibrotic disease |
WO2010091386A2 (en) | 2009-02-06 | 2010-08-12 | Rfs Pharma, Llc | Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections |
ES2628842T3 (es) | 2009-02-10 | 2017-08-04 | Gilead Sciences, Inc. | Método para la preparación de tieno[3,4-d]pirimidin-7-il ribósidos |
WO2010101967A2 (en) | 2009-03-04 | 2010-09-10 | Idenix Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole hcv polymerase inhibitors |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
UA108986C2 (xx) | 2009-05-14 | 2015-07-10 | Мілленніум Фармасьютікалз, Інк. | Кристалічна форма гідрохлориду ((1s,2s,4r)-4-{4-$(1s)-2,3-дигідро-1h-інден-1-іламіно]-7h-піроло$2,3-d]піримідин-7іл}-2-гідроксициклопентил)метилсульфамату (варіанти) |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
EP2459582B1 (en) | 2009-07-30 | 2015-05-27 | Merck Sharp & Dohme Corp. | Hepatitis c virus ns3 protease inhibitors |
WO2011014882A1 (en) | 2009-07-31 | 2011-02-03 | Medtronic, Inc. | CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS |
US9284307B2 (en) | 2009-08-05 | 2016-03-15 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors |
PE20160217A1 (es) | 2009-09-21 | 2016-05-18 | Gilead Sciences Inc | Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales |
US8455451B2 (en) | 2009-09-21 | 2013-06-04 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
US7973013B2 (en) | 2009-09-21 | 2011-07-05 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
CA2773773C (en) | 2009-09-21 | 2019-04-23 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs |
CA2777741A1 (en) | 2009-10-16 | 2011-04-21 | Rib-X Pharmaceuticals, Inc. | Antimicrobial compounds and methods of making and using the same |
TW201125566A (en) * | 2009-10-16 | 2011-08-01 | Rib X Pharmaceuticals Inc | Antimicrobial compounds and methods of making and using the same |
EP2488532B1 (en) | 2009-10-16 | 2018-05-09 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
BR112012011221A2 (pt) | 2009-11-14 | 2016-04-05 | Hoffmann La Roche | biomarcadores para prever resposta rápida ao tratamento de hcv |
US20110117055A1 (en) | 2009-11-19 | 2011-05-19 | Macdonald James E | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds |
EP2507636A1 (en) | 2009-12-02 | 2012-10-10 | F. Hoffmann-La Roche AG | Biomarkers for predicting sustained response to hcv treatment |
CA2784748A1 (en) | 2009-12-18 | 2011-06-23 | Idenix Pharmaceuticals, Inc. | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
RU2556991C2 (ru) * | 2010-01-28 | 2015-07-20 | Рибосайенс Ллк | 4'-азидонуклеозиды, активные в отношении hcv |
CA2794671C (en) | 2010-03-31 | 2018-05-01 | Gilead Pharmasset Llc | Stereoselective synthesis of phosphorus containing actives |
TWI515000B (zh) | 2010-04-01 | 2016-01-01 | 伊迪尼克製藥公司 | 用於治療病毒感染之化合物及醫藥組合物 |
CZ303327B6 (cs) * | 2010-04-29 | 2012-08-01 | Univerzita Palackého v Olomouci | Substitucní deriváty N6-benzyladenosin-5´-monofosfátu, zpusoby jejich prípravy, tyto deriváty pro použití jako léciva a terapeutický prípravek je obsahující |
TW201201815A (en) | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
KR102108864B1 (ko) | 2010-07-19 | 2020-05-12 | 길리애드 사이언시즈, 인코포레이티드 | 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법 |
SI2595980T1 (sl) | 2010-07-22 | 2014-11-28 | Gilead Sciences, Inc. | Postopki in sestavki za zdravljenje paramyxoviridae virusnih infekcij |
TW201211614A (en) | 2010-09-10 | 2012-03-16 | Genius Electronic Optical Co Ltd | Imaging lens composed of four lenses and electronic device using the same |
TW201305185A (zh) * | 2010-09-13 | 2013-02-01 | Gilead Sciences Inc | 用於抗病毒治療之2’-氟取代之碳-核苷類似物 |
EP2619206A1 (en) | 2010-09-20 | 2013-07-31 | Gilead Sciences, Inc. | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment |
BR112013008510A2 (pt) | 2010-10-08 | 2016-07-05 | Novartis Ag | vitamina e formulações de inibidores de sulfamida ns3 |
WO2012075140A1 (en) | 2010-11-30 | 2012-06-07 | Pharmasset, Inc. | Compounds |
WO2012080050A1 (en) | 2010-12-14 | 2012-06-21 | F. Hoffmann-La Roche Ag | Solid forms of a phenoxybenzenesulfonyl compound |
TW201309690A (zh) | 2011-02-10 | 2013-03-01 | Idenix Pharmaceuticals Inc | 巨環絲胺酸蛋白酶抑制劑,其醫藥組合物及其於治療hcv感染之用途 |
CN102649788B (zh) * | 2011-02-28 | 2015-03-25 | 四川大学 | β-L-2’-脱氧-胸腺嘧啶核苷衍生物及其制备方法和用途 |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
JP2014514295A (ja) | 2011-03-31 | 2014-06-19 | アイディニックス ファーマシューティカルズ インコーポレイテッド | ウイルス感染の治療のための化合物および薬学的組成物 |
US8877733B2 (en) | 2011-04-13 | 2014-11-04 | Gilead Sciences, Inc. | 1′-substituted pyrimidine N-nucleoside analogs for antiviral treatment |
US9156872B2 (en) | 2011-04-13 | 2015-10-13 | Merck Sharp & Dohme Corp. | 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
US9061041B2 (en) | 2011-04-13 | 2015-06-23 | Merck Sharp & Dohme Corp. | 2′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
AU2012242978A1 (en) | 2011-04-13 | 2013-10-24 | Merck Sharp & Dohme Corp. | 2'-Cyano Substituted Nucleoside Derivatives and methods of use thereof for the treatment of viral diseases |
US10226478B2 (en) | 2011-04-14 | 2019-03-12 | Cyclacel Limited | Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia |
EP2731434A4 (en) | 2011-07-13 | 2014-12-31 | Merck Sharp & Dohme | 5'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES |
US9408863B2 (en) | 2011-07-13 | 2016-08-09 | Merck Sharp & Dohme Corp. | 5′-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases |
TW201329096A (zh) | 2011-09-12 | 2013-07-16 | Idenix Pharmaceuticals Inc | 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物 |
CA2847892A1 (en) | 2011-09-12 | 2013-03-21 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
CN106166160A (zh) | 2011-09-16 | 2016-11-30 | 吉利德制药有限责任公司 | 用于治疗hcv的组合物 |
AR089650A1 (es) | 2011-10-14 | 2014-09-10 | Idenix Pharmaceuticals Inc | Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales |
EP2776405A1 (en) | 2011-11-11 | 2014-09-17 | Pfizer Inc | 2-thiopyrimidinones |
US9328138B2 (en) | 2011-11-15 | 2016-05-03 | Msd Italia S.R.L. | HCV NS3 protease inhibitors |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
EP3750544A3 (en) | 2011-11-30 | 2021-03-24 | Emory University | Jak inhibitors for use in the prevention or treatment of viral infection |
AP2014007796A0 (en) | 2011-12-22 | 2014-07-31 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
WO2013106344A1 (en) | 2012-01-12 | 2013-07-18 | Ligand Pharmaceuticals, Inc. | 2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5' |
WO2013133927A1 (en) | 2012-02-13 | 2013-09-12 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate] |
JP6242378B2 (ja) * | 2012-03-13 | 2017-12-06 | ギリアード サイエンシーズ, インコーポレイテッド | 抗ウイルス処置のための2’−置換カルバヌクレオシド類似体 |
ES2710506T3 (es) * | 2012-03-21 | 2019-04-25 | Alios Biopharma Inc | Nucleósidos sustituidos, nucleótidos y sus análogos |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
SG11201407674TA (en) | 2012-05-22 | 2014-12-30 | Idenix Pharmaceuticals Inc | D-amino acid compounds for liver disease |
WO2013177195A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphate prodrugs for hcv infection |
WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
AR091156A1 (es) | 2012-05-25 | 2015-01-14 | Jansen R & D Ireland | Nucleosidos de espirooxetano de uracilo |
US9994604B2 (en) | 2012-05-31 | 2018-06-12 | Bio-Lab Ltd. | Pyrazolotriazolyl nucleoside analogues and oligonucleotides comprising them |
US9192621B2 (en) | 2012-09-27 | 2015-11-24 | Idenix Pharmaceuticals Llc | Esters and malonates of SATE prodrugs |
TR201809048T4 (tr) | 2012-10-08 | 2018-07-23 | Centre Nat Rech Scient | Hcv enfeksiyonu için 2'-kloro nükleosit analogları. |
WO2014063019A1 (en) | 2012-10-19 | 2014-04-24 | Idenix Pharmaceuticals, Inc. | Dinucleotide compounds for hcv infection |
EP2909222B1 (en) | 2012-10-22 | 2021-05-26 | Idenix Pharmaceuticals LLC | 2',4'-bridged nucleosides for hcv infection |
MX2015005500A (es) * | 2012-10-29 | 2016-02-09 | Cocrystal Pharma Inc | Nucleotidos de pirimidina y sus profarmacos de monofosfato para el tratamiento de infecciones virales y cancer. |
WO2014078427A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-alanine ester of rp-nucleoside analog |
CN102924552B (zh) * | 2012-11-14 | 2014-09-10 | 南京中医药大学 | 一种具有抗疱疹病毒作用的化合物 |
WO2014078436A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-alanine ester of sp-nucleoside analog |
WO2014078652A1 (en) * | 2012-11-16 | 2014-05-22 | Zs Genetics, Inc. | Heavy atom labeled nucleosides, nucleotides, and nucleic acid polymers, and uses thereof |
WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
EP2935305A4 (en) * | 2012-12-21 | 2016-08-03 | Alios Biopharma Inc | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUE THEREOF |
PT2935303T (pt) | 2012-12-21 | 2021-04-30 | Alios Biopharma Inc | 4'-fluoro-nucleósidos, 4'-fluoro-nucleótidos e seus análogos para o tratamento de hcv |
CN102977170B (zh) * | 2012-12-26 | 2015-04-22 | 南京亚东启天药业有限公司 | 一种工业化生产卡培他滨中间体的合成工艺 |
US20140212491A1 (en) | 2013-01-31 | 2014-07-31 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
US10034893B2 (en) | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
WO2014121418A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
WO2014121417A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
US9309275B2 (en) | 2013-03-04 | 2016-04-12 | Idenix Pharmaceuticals Llc | 3′-deoxy nucleosides for the treatment of HCV |
US20140271547A1 (en) | 2013-03-13 | 2014-09-18 | Idenix Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
RU2534613C2 (ru) | 2013-03-22 | 2014-11-27 | Александр Васильевич Иващенко | Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения |
US9187515B2 (en) | 2013-04-01 | 2015-11-17 | Idenix Pharmaceuticals Llc | 2′,4′-fluoro nucleosides for the treatment of HCV |
BR112015025766A2 (pt) | 2013-04-12 | 2017-10-17 | Achillion Pharmaceuticals Inc | derivado de nucleosídeo altamente ativo para o tratamento de hcv |
WO2014197578A1 (en) | 2013-06-05 | 2014-12-11 | Idenix Pharmaceuticals, Inc. | 1',4'-thio nucleosides for the treatment of hcv |
US20150037282A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
EP4005560A1 (en) | 2013-08-27 | 2022-06-01 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
UA117375C2 (uk) | 2013-09-04 | 2018-07-25 | Медівір Аб | Інгібітори полімерази hcv |
WO2015035421A1 (en) | 2013-09-09 | 2015-03-12 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
SG11201601654TA (en) | 2013-09-09 | 2016-04-28 | Melinta Therapeutics Inc | Antimicrobial compunds and methods of making and using the same |
US20160229866A1 (en) | 2013-09-20 | 2016-08-11 | Idenix Pharmaceuticals Inc. | Hepatitis c virus inhibitors |
WO2015061683A1 (en) | 2013-10-25 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv |
EP3063165A1 (en) | 2013-11-01 | 2016-09-07 | Idenix Pharmaceuticals LLC | D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv |
UA119050C2 (uk) | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
EP3074399A1 (en) | 2013-11-27 | 2016-10-05 | Idenix Pharmaceuticals LLC | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
CN103709221B (zh) * | 2013-12-05 | 2016-04-27 | 湖南科源生物制品有限公司 | 一种虫草素的制备方法 |
US10683321B2 (en) | 2013-12-18 | 2020-06-16 | Idenix Pharmaceuticals Llc | 4′-or nucleosides for the treatment of HCV |
KR102327464B1 (ko) | 2014-02-06 | 2021-11-16 | 리보사이언스 엘엘씨 | 인플루엔자 rna 복제의 저해제로서의 4'-다이플루오로메틸 치환된 뉴클레오사이드 유도체 |
AU2015217221A1 (en) | 2014-02-13 | 2016-08-11 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
CN103819524B (zh) * | 2014-03-04 | 2016-04-13 | 郑州格然林医药科技有限公司 | 3’-氟取代嘌呤核苷类似物、其制备方法及其应用 |
WO2015134561A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
WO2015134560A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
EP3131914B1 (en) | 2014-04-16 | 2023-05-10 | Idenix Pharmaceuticals LLC | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
SI3160476T1 (sl) * | 2014-06-24 | 2021-05-31 | Janssen Biopharma, Inc. | Substituirani nukleozidi, nukleotidi in njihovi analogi, za uporabo v zdravljenju virusne okužbe |
CN106687118A (zh) | 2014-07-02 | 2017-05-17 | 配体药物公司 | 前药化合物及其用途 |
CN104961787B (zh) * | 2014-07-10 | 2020-06-26 | 深圳松乐生物科技有限公司 | 一种虫草素的合成方法 |
AU2015301248B2 (en) | 2014-08-04 | 2018-10-04 | Auburn University | Enantiomers of the 1',6'-isomer of Neplanocin A |
TWI673283B (zh) * | 2014-08-21 | 2019-10-01 | 美商基利科學股份有限公司 | 2’-氯胺基嘧啶酮及嘧啶二酮核苷類 |
WO2016033164A1 (en) | 2014-08-26 | 2016-03-03 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
MY171137A (en) * | 2014-09-11 | 2019-09-27 | Univ Sains Malaysia | Thioguanine derivatives |
TWI740546B (zh) | 2014-10-29 | 2021-09-21 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
WO2016073756A1 (en) | 2014-11-06 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Deuterated nucleoside/tide derivatives |
US9732110B2 (en) | 2014-12-05 | 2017-08-15 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
BR112017013858A2 (pt) * | 2014-12-26 | 2018-02-27 | Univ Emory | n4-hidroxicitidina e derivados e usos antivirais relacionados aos mesmos |
WO2016134057A1 (en) * | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
KR102363946B1 (ko) | 2015-03-06 | 2022-02-17 | 아테아 파마슈티컬즈, 인크. | HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드 |
US10947237B2 (en) | 2015-03-11 | 2021-03-16 | BioVersys AG | Antimicrobial compounds and methods of making and using the same |
MX2017014128A (es) | 2015-05-05 | 2018-03-15 | Pfizer | 2-tiopirimidinonas. |
CN107743491B (zh) * | 2015-05-08 | 2020-08-21 | 豪夫迈·罗氏有限公司 | 用于治疗和预防病毒感染的新的氧硫杂环戊烷甲酸及其衍生物 |
EP3344642A1 (en) | 2015-09-02 | 2018-07-11 | AbbVie Inc. | Anti-viral tetrahydrofurane derivatives |
MA52371A (fr) | 2015-09-16 | 2021-09-22 | Gilead Sciences Inc | Méthodes de traitement d'infections dues aux coronaviridae |
CN105566304B (zh) * | 2016-01-13 | 2019-04-30 | 大连大学 | 含硫尿苷抗癌化合物及其中间体和制备方法 |
WO2017156380A1 (en) * | 2016-03-10 | 2017-09-14 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
WO2017156391A1 (en) * | 2016-03-11 | 2017-09-14 | Spring Bank Pharmaceuticals, Inc. | Compounds and compositions for the treatment of infections |
EP3452479A1 (en) | 2016-05-06 | 2019-03-13 | Melinta Therapeutics, Inc. | Antimicrobials and methods of making and using same |
US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
EP4088725A1 (en) | 2016-09-07 | 2022-11-16 | ATEA Pharmaceuticals, Inc. | 2'-substituted-n6-substituted purine nucleotides for the treatment of a virus from the picornaviridae family |
UA127407C2 (uk) | 2017-02-01 | 2023-08-16 | Атеа Фармасеутікалс, Інк. | Гемісульфатна сіль нуклеотиду для лікування спричиненого вірусом гепатиту с захворювання |
CN116036112A (zh) | 2017-03-14 | 2023-05-02 | 吉利德科学公司 | 治疗猫冠状病毒感染的方法 |
CA3178212A1 (en) | 2017-05-01 | 2018-11-08 | Gilead Sciences, Inc. | Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
CN107033205B (zh) * | 2017-06-12 | 2020-05-19 | 上海兆维科技发展有限公司 | 一种3’-脱氧尿苷的制备方法 |
CN111093627B (zh) | 2017-07-11 | 2024-03-08 | 吉利德科学公司 | 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物 |
CN107383011B (zh) * | 2017-08-01 | 2019-05-10 | 深圳百奥捷生物科技有限公司 | 一种分离自连翘叶黄芩的抗病毒生物碱及其制备方法 |
CN107253951B (zh) * | 2017-08-01 | 2019-05-10 | 深圳百奥捷生物科技有限公司 | 一种嘌呤生物碱及其作为抗rsv病毒药物的应用 |
KR200486741Y1 (ko) | 2017-08-24 | 2018-06-27 | 류제웅 | 디스크 치료 또는 완화기구 |
KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
EP3737676B1 (en) | 2018-01-09 | 2024-03-06 | Ligand Pharmaceuticals, Inc. | Acetal compounds and therapeutic uses thereof |
JP2021521118A (ja) | 2018-04-10 | 2021-08-26 | アテア ファーマシューティカルズ, インコーポレイテッド | 肝硬変を伴うhcv感染患者の治療 |
KR20210035095A (ko) | 2018-05-25 | 2021-03-31 | 프리뮨 테라퓨틱스, 인크. | Tlr7 효능제 |
CN108676048B (zh) * | 2018-06-04 | 2021-04-27 | 上海兆维科技发展有限公司 | 一种虫草素的制备方法 |
US11446303B2 (en) | 2019-06-21 | 2022-09-20 | Tosk, Inc. | Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions |
MX2022006307A (es) | 2019-11-26 | 2022-08-22 | Primmune Therapeutics Inc | Agonistas del receptor tipo toll 7 (tlr7). |
AU2021214911A1 (en) | 2020-01-27 | 2022-07-21 | Gilead Sciences, Inc. | Methods for treating SARS CoV-2 infections |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
US11613553B2 (en) | 2020-03-12 | 2023-03-28 | Gilead Sciences, Inc. | Methods of preparing 1′-cyano nucleosides |
EP4132651A1 (en) | 2020-04-06 | 2023-02-15 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
CN111675660B (zh) * | 2020-05-07 | 2021-12-10 | 奥锐特药业股份有限公司 | 一种合成帕博西尼中间体的制备方法及合成帕博西尼的方法 |
EP4153189A1 (en) * | 2020-05-22 | 2023-03-29 | Merck Sharp & Dohme LLC | Synthesis of fluorinated nucleotides |
WO2021243157A1 (en) | 2020-05-29 | 2021-12-02 | Gilead Sciences, Inc. | Remdesivir treatment methods |
BR112022026321A2 (pt) | 2020-06-24 | 2023-01-17 | Gilead Sciences Inc | Análogos de 1'-ciano nucleosídeo e usos dos mesmos |
WO2022047065A2 (en) | 2020-08-27 | 2022-03-03 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
CN112608357B (zh) * | 2020-12-21 | 2022-12-09 | 杭州科巢生物科技有限公司 | 一种抗病毒药物Molnupiravir的制备方法 |
CN115215914B (zh) * | 2021-04-15 | 2024-05-28 | 中国科学院上海药物研究所 | 核苷类似物及其用途 |
WO2022245814A1 (en) * | 2021-05-17 | 2022-11-24 | Rome Therapeutics, Inc. | Methods of treating medical conditions and inhibiting line1 reverse transcriptase using a substituted 4-fluoro-2,5-dihydrofuranyl phosphonic acid or related compound |
CN113307833B (zh) * | 2021-06-16 | 2022-07-05 | 苏州立新制药有限公司 | N4-羟基胞苷的制备方法 |
US11541071B1 (en) | 2021-12-16 | 2023-01-03 | Ascletis BioScience Co., Ltd | Nucleoside derivatives and methods of use thereof |
KR20230001778U (ko) | 2022-03-02 | 2023-09-11 | 류제웅 | 디스크 완화용 수면복대 |
EP4320128A1 (en) | 2022-03-02 | 2024-02-14 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
CN115536710B (zh) * | 2022-10-18 | 2024-04-16 | 南京工业大学 | 一种高品质胞苷硫酸盐晶体的制备方法 |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4232154A (en) * | 1977-12-13 | 1980-11-04 | United States Of America | Carbocyclic analogs of cytosine nucleosides exhibiting antiviral and antineoplasticactivity |
US4211773A (en) * | 1978-10-02 | 1980-07-08 | Sloan Kettering Institute For Cancer Research | 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides |
JPS608270A (ja) * | 1983-06-29 | 1985-01-17 | Yoshitomi Pharmaceut Ind Ltd | シクロペンテン環を有する新規ヌクレオシド |
US4666892A (en) * | 1984-03-06 | 1987-05-19 | Sloan-Kettering Memorial Cancer Center | Method and composition for hepatitis treatment with pyrimidine nucleoside compounds |
JPS6187673A (ja) * | 1984-10-06 | 1986-05-06 | Yoshitomi Pharmaceut Ind Ltd | アシルシトシン誘導体 |
JPS61130299A (ja) * | 1984-11-30 | 1986-06-18 | Daikin Ind Ltd | 5−フルオロシチシン化合物塩酸塩の製法 |
US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
US4968690A (en) * | 1986-05-27 | 1990-11-06 | United States Government As Represented By The Secretary Of The Dept. Of Health And Human Services | 3-deazaneplanocin, intermediates for it, and antiviral composition and method of treatment using it |
US4975434A (en) * | 1986-05-27 | 1990-12-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antiviral and anticancer cyclopentenyl cytosine |
US5446029A (en) * | 1986-07-04 | 1995-08-29 | Medivir Ab | Anti-retroviral activity of 2',3'-dideoxy-3'-fluoronucleosides |
EP0277599A3 (en) * | 1987-01-30 | 1990-05-09 | Asahi Glass Company Ltd. | Fluorine containing cyclopentane derivatives and processes for their production |
SE8701605D0 (sv) | 1987-04-16 | 1987-04-16 | Astra Ab | Novel medicinal compounds |
GB8712115D0 (en) | 1987-05-22 | 1987-06-24 | Hoffmann La Roche | Pyrimidine derivatives |
US4835104A (en) * | 1987-06-16 | 1989-05-30 | Ajinomoto Co., Inc., Patent & Licensing Department | Process for producing and purifying 2',3'-dideoxynucleosides, and process for producing 2',3'-dideoxy-2',3'-didehydronucleosides |
JPS6442499A (en) * | 1987-08-10 | 1989-02-14 | Yoshitomi Pharmaceutical | Cytosine derivative of racemic type |
IL87646A (en) * | 1987-09-03 | 1994-07-31 | Sloan Kettering Inst Cancer | Preparation for the treatment of hepatitis virus containing 1 -) 2 '- Deoxy - 2' - Fluoro - Beta - B - D - Arabino - Furanozil (- 5 - Orcil |
US5246924A (en) * | 1987-09-03 | 1993-09-21 | Sloan-Kettering Institute For Cancer Research | Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil |
JPH03501253A (ja) | 1987-09-22 | 1991-03-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | エイズ(aids)治療を目的とするリポソームによるヌクレオシド類似物質 |
US4908440A (en) | 1987-11-12 | 1990-03-13 | Bristol Myers Company | 2',3'-dideoxy-2'-fluoroarabinopyrimidine nucleosides |
SE8802173D0 (sv) | 1988-06-10 | 1988-06-10 | Astra Ab | Pyrimidine derivatives |
SE8802687D0 (sv) | 1988-07-20 | 1988-07-20 | Astra Ab | Nucleoside derivatives |
US5035878A (en) | 1988-09-12 | 1991-07-30 | University Of Rochester | Use of dithiocarbamates to counteract myelosuppression |
US5034518A (en) * | 1989-05-23 | 1991-07-23 | Southern Research Institute | 2-fluoro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine nucleosides |
US5194654A (en) | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
DD293498A5 (de) | 1989-07-20 | 1991-09-05 | Zi Fuer Molekularbiologie Der Adw,De | Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier |
GB8920534D0 (en) | 1989-09-11 | 1989-10-25 | Wellcome Found | Antiviral compounds |
US5886162A (en) * | 1989-11-03 | 1999-03-23 | Research Foundation Of State University Of New York | Lipophilic diakylaminomethylene prodrug derivatives for the inhibition of replication of viruses |
US5463092A (en) | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
US5026687A (en) | 1990-01-03 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds |
US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
GB9007569D0 (en) * | 1990-04-04 | 1990-05-30 | Nycomed As | Carbo-nucleoside derivatives |
AU7872491A (en) | 1990-05-07 | 1991-11-27 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
AU7623991A (en) | 1990-05-17 | 1991-11-21 | Syntex (U.S.A.) Inc. | Antiviral agents |
US5192749A (en) * | 1990-05-21 | 1993-03-09 | Syntex (U.S.A.) Inc. | 4'-substituted nucleosides |
JPH05507279A (ja) | 1990-05-29 | 1993-10-21 | ネクススター・ファーマシューティカルズ・インコーポレイテッド | グリセロールジ―およびトリホスフェート誘導体の合成 |
DK0533833T3 (da) | 1990-06-13 | 1996-04-22 | Arnold Glazier | Phosphorprolægemidler |
US5256641A (en) | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
US5543389A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
US5149794A (en) | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
IT1246983B (it) | 1990-11-13 | 1994-12-12 | Consiglio Nazionale Ricerche | L-2'-desossiuridine e composizioni farmaceutiche che le contengono. |
NZ241625A (en) | 1991-02-22 | 1996-03-26 | Univ Emory | 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers |
EP0594677A4 (en) | 1991-07-12 | 1997-09-17 | Vical Inc | Antiviral liponucleosides: treatment of hepatitis b |
US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
IL106204A0 (en) * | 1992-07-02 | 1993-11-15 | Wellcome Found | Nucleosides,their preparation and pharmaceutical compositions containing them |
US6080791A (en) * | 1992-07-24 | 2000-06-27 | Seres Laboratories, Inc. | Method of treating a viral condition by inhibiting membrane fusion |
JPH06107548A (ja) | 1992-08-10 | 1994-04-19 | Nippon Kayaku Co Ltd | 癌の肝転移抑制剤及び肝癌の治療剤 |
JPH0665211A (ja) | 1992-08-21 | 1994-03-08 | Yoshitomi Pharmaceut Ind Ltd | シクロペンタンヌクレオシド化合物 |
JPH0680688A (ja) * | 1992-09-03 | 1994-03-22 | Asahi Breweries Ltd | 4’−メチルヌクレオシド誘導体 |
US6174868B1 (en) | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
EP0626970A1 (en) | 1992-12-18 | 1994-12-07 | The University Of Alberta | Dihydropyrimidine nucleosides with antiviral properties |
US5512671A (en) * | 1993-02-16 | 1996-04-30 | Wake Forest University | Ether lipid-nucleoside covalent conjugates |
US5496546A (en) | 1993-02-24 | 1996-03-05 | Jui H. Wang | Compositions and methods of application of reactive antiviral polyadenylic acid derivatives |
US5654286A (en) | 1993-05-12 | 1997-08-05 | Hostetler; Karl Y. | Nucleotides for topical treatment of psoriasis, and methods for using same |
AU701574B2 (en) | 1993-05-12 | 1999-02-04 | Karl Y. Hostetler | Acyclovir derivatives for topical use |
EP0773029A4 (en) | 1993-07-19 | 1997-09-03 | Tokyo Tanabe Co | HEPATITIS C VIRUS PROLIFERATION INHIBITOR |
JP3487441B2 (ja) | 1993-09-22 | 2004-01-19 | 株式会社デンソー | リチウム二次電池用活物質の製造方法 |
US5587362A (en) | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
DE4432623A1 (de) | 1994-09-14 | 1996-03-21 | Huels Chemische Werke Ag | Verfahren zur Bleichung von wäßrigen Tensidlösungen |
US5696277A (en) | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
US5703058A (en) | 1995-01-27 | 1997-12-30 | Emory University | Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent |
US5808040A (en) * | 1995-01-30 | 1998-09-15 | Yale University | L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides |
JP3786447B2 (ja) | 1995-03-31 | 2006-06-14 | エーザイ株式会社 | C型肝炎の予防・治療剤 |
US5955059A (en) | 1995-06-06 | 1999-09-21 | Trustees Of Boston University | Use of locally applied DNA fragments |
WO1996040164A1 (en) | 1995-06-07 | 1996-12-19 | Emory University | Nucleosides with anti-hepatitis b virus activity |
GB9517022D0 (en) * | 1995-08-19 | 1995-10-25 | Glaxo Group Ltd | Medicaments |
US5744460A (en) | 1996-03-07 | 1998-04-28 | Novartis Corporation | Combination for treatment of proliferative diseases |
US5633388A (en) | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
US5830905A (en) | 1996-03-29 | 1998-11-03 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
US5891874A (en) | 1996-06-05 | 1999-04-06 | Eli Lilly And Company | Anti-viral compound |
US6180604B1 (en) | 1996-08-21 | 2001-01-30 | Micrologix Biotech Inc. | Compositions and methods for treating infections using analogues of indolicidin |
JP3927630B2 (ja) | 1996-09-27 | 2007-06-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウイルス感染症の予防・治療剤 |
US5922757A (en) | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
ZA979327B (en) | 1996-10-18 | 1998-05-11 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease. |
JP2001525797A (ja) * | 1996-10-28 | 2001-12-11 | ザ ユニバーシティ オブ ワシントン | ウイルスrnaへのミスコーディングリボヌクレオシドアナログの組込みによるウイルス変異の誘導 |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
WO1998039013A1 (en) | 1997-03-04 | 1998-09-11 | Peregrine Pharmaceutical, Inc. | Composition and method for treating cancer and immunological disorders resulting in chronic conditions |
IL133235A (en) | 1997-06-30 | 2004-02-19 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexane nmda receptor antagonists and pharmaceutical compositions comprising them |
CA2294562C (en) | 1997-08-11 | 2005-07-26 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
US20020006913A1 (en) | 1997-11-04 | 2002-01-17 | Von Borstel Reid W. | Antimutagenic compositions for treatment and prevention of photodamage to skin |
EA200700564A1 (ru) * | 1998-02-25 | 2007-08-31 | Эмори Юниверсити | 2`-фторнуклеозиды |
GB9806815D0 (en) | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
WO1999058126A1 (en) | 1998-05-11 | 1999-11-18 | The Endowment For Research In Human Biology, Inc. | Use of neomycin for treating angiogenesis-related diseases |
AU2023400A (en) | 1998-11-12 | 2000-05-29 | Children's Medical Center Corporation | Compositions and methods for inhibiting angiogenesis using trna and fragments thereof |
WO2000047198A2 (en) | 1999-02-12 | 2000-08-17 | G.D. Searle & Co. | Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
EP1173161A2 (en) | 1999-02-12 | 2002-01-23 | G.D. SEARLE & CO. | Glucamine compounds for treating hepatitis virus infections |
AU1262001A (en) | 1999-11-04 | 2001-05-14 | Biochem Pharma Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
CN1919859A (zh) * | 1999-11-12 | 2007-02-28 | 法玛赛特有限公司 | 2'-脱氧-l-核苷的合成 |
US6518253B1 (en) | 1999-11-19 | 2003-02-11 | Robert Tam | Treatment of viral infections using the L-isomer of ribavirin |
AU2001235278A1 (en) * | 2000-02-18 | 2001-08-27 | Shire Biochem Inc | Method for the treatment or prevention of flavivirus infections using nucleoside analogues |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
DE60105424T2 (de) | 2000-05-26 | 2005-09-22 | Idenix (Cayman) Ltd. | Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden |
CA2410579C (en) | 2000-05-26 | 2010-04-20 | Jean-Pierre Sommadossi | Methods and compositions for treating flaviviruses and pestiviruses |
US20030008841A1 (en) * | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
KR101005299B1 (ko) | 2000-10-18 | 2011-01-04 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 |
EP2145965A1 (en) | 2000-10-18 | 2010-01-20 | Pharmasset, Inc. | Multiplex quantification of nucleic acids in diseased cells |
-
2001
- 2001-10-18 KR KR1020097000004A patent/KR101005299B1/ko active IP Right Grant
- 2001-10-18 US US10/045,292 patent/US20030087873A1/en not_active Abandoned
- 2001-10-18 KR KR1020097016705A patent/KR20090089922A/ko not_active Application Discontinuation
- 2001-10-18 AU AU2874902A patent/AU2874902A/xx active Pending
- 2001-10-18 KR KR10-2003-7005461A patent/KR20040028657A/ko not_active Application Discontinuation
- 2001-10-18 KR KR1020117007042A patent/KR101195019B1/ko active IP Right Grant
- 2001-10-18 CN CN01820816.9A patent/CN1646141B/zh not_active Expired - Lifetime
- 2001-10-18 EP EP10175643A patent/EP2251015B1/en not_active Expired - Lifetime
- 2001-10-18 BR BRPI0114837-0A patent/BR0114837A/pt not_active Application Discontinuation
- 2001-10-18 DK DK01987756.2T patent/DK1411954T3/da active
- 2001-10-18 KR KR1020087007867A patent/KR100905221B1/ko active IP Right Grant
- 2001-10-18 AU AU2002228749A patent/AU2002228749B2/en not_active Expired
- 2001-10-18 AT AT01987756T patent/ATE491459T1/de active
- 2001-10-18 JP JP2002536301A patent/JP2004533406A/ja not_active Withdrawn
- 2001-10-18 PT PT101756435T patent/PT2251015E/pt unknown
- 2001-10-18 EP EP01987756A patent/EP1411954B1/en not_active Expired - Lifetime
- 2001-10-18 DK DK10175643.5T patent/DK2251015T3/da active
- 2001-10-18 PT PT01987756T patent/PT1411954E/pt unknown
- 2001-10-18 ES ES10175643T patent/ES2402597T3/es not_active Expired - Lifetime
- 2001-10-18 WO PCT/US2001/046113 patent/WO2002032920A2/en active Application Filing
- 2001-10-18 CA CA2426187A patent/CA2426187C/en not_active Expired - Lifetime
- 2001-10-18 DE DE60143672T patent/DE60143672D1/de not_active Expired - Lifetime
- 2001-10-18 CN CN201010192903.6A patent/CN101862345B/zh not_active Expired - Lifetime
- 2001-10-18 KR KR1020107014460A patent/KR101201552B1/ko active IP Right Grant
-
2005
- 2005-11-22 HK HK05110563.1A patent/HK1078482A1/xx not_active IP Right Cessation
-
2008
- 2008-07-24 AU AU2008203296A patent/AU2008203296A1/en not_active Abandoned
-
2009
- 2009-02-04 JP JP2009023369A patent/JP2009161541A/ja not_active Withdrawn
-
2010
- 2010-07-01 JP JP2010150966A patent/JP2011012062A/ja not_active Ceased
- 2010-08-05 US US12/805,563 patent/US20110269707A1/en not_active Abandoned
-
2011
- 2011-03-11 CY CY20111100278T patent/CY1111332T1/el unknown
- 2011-03-16 HK HK11102651.3A patent/HK1148470A1/xx not_active IP Right Cessation
-
2012
- 2012-06-04 AU AU2012203287A patent/AU2012203287A1/en not_active Abandoned
- 2012-12-03 JP JP2012264126A patent/JP2013079250A/ja active Pending
-
2013
- 2013-06-03 US US13/908,098 patent/US10100076B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1148470A1 (en) | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation | |
WO2002048165A3 (en) | Antiviral agents for treatment of flaviviridae infections | |
BR0309581A (pt) | Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c | |
BR0307712A (pt) | Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal | |
HK1161231A1 (en) | Viral inhibitors | |
EG24465A (en) | Nucleoside derivatives as inhibitors of RNA dependent RNA viral polymerase | |
WO2006063281A3 (en) | 2' and 3' - substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | |
AU2003291885A1 (en) | Compounds and methods for the treatment or prevention of flavivirus infections | |
EP1572097A4 (en) | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF INFECTIONS WITH THE HEPATITIS C-VIRUS | |
WO2002062290A3 (en) | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | |
ATE245641T1 (de) | Antivirale pyrimidinderivate | |
SG161315A1 (en) | Compounds and methods for the treatment or prevention of flavivirus infections | |
AP2005003212A0 (en) | Modified 2' and 3' nucleoside prodrugs for treating flaviviridae infections. | |
BRPI0410846A (pt) | compostos, composições e usos para o tratamento de uma infecção por flaviviridae | |
WO2003053344A3 (en) | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | |
ID27290A (id) | Penggunaan senyawa 1,5-dideoksi-1,5-imino-d-glusitol tersubstitusi-n pada pengobatan infeksi virus hepatitis | |
WO2004084796A3 (en) | Compounds for the treatment of flaviviridae infections | |
WO2001008672A3 (en) | Glucamine compounds for treating hepatitis virus infections | |
WO2004052905A3 (en) | Antiviral nucleoside derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE | Patent expired |
Effective date: 20211017 |